Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jacquelyn Lahoud

Infectious Disease Brooklyn, NY Medical Doctor

NPI 1801114624 CMS profile 1339832

7515 13Th Ave, Brooklyn, NY 11228

Open in the dashboard

General payments

$6,330

254 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jacquelyn Lahoud of Brooklyn, NY is reported in the CMS Open Payments database as having received $6,330 across 254 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $191 7
2024 General $322 13
2023 General $927 43
2022 General $1,472 55
2021 General $1,081 44
2020 General $1,189 48
2019 General $1,147 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jacquelyn Lahoud
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Jacquelyn Lahoud were reported at $191. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Jacquelyn Lahoud Infectious Disease median Middle half National median
2019 $1,147 $190 $60–$862 $163
2020 $1,189 $124 $32–$606 $114
2021 $1,081 $148 $38–$905 $132
2022 $1,472 $166 $50–$834 $149
2023 $927 $171 $57–$787 $160
2024 $322 $176 $52–$752 $164
2025 $191 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $1,035 31 payments
  2. AbbVie, Inc. $893 41 payments
  3. GlaxoSmithKline, LLC. $478 15 payments
  4. Shionogi Inc $468 23 payments
  5. Merck Sharp & Dohme Corporation $368 19 payments
  6. Novo Nordisk Inc $332 15 payments
  7. AstraZeneca Pharmaceuticals LP $311 11 payments
  8. Janssen Pharmaceuticals, Inc $290 15 payments
  9. Pfizer Inc. $288 13 payments
  10. Paratek Pharmaceuticals, Inc. $276 13 payments
  11. Other $1,590 58 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,304 251 payments
  2. Education $26 3 payments
Products named General payments · program years 2019–2025
  1. JARDIANCE $1,035 31 payments
  2. VRAYLAR $527 23 payments
  3. Fetroja $468 23 payments
  4. TRELEGY ELLIPTA $383 11 payments
  5. XARELTO $290 15 payments
  6. Ozempic $289 13 payments
  7. NUZYRA $276 13 payments
  8. AVYCAZ $180 9 payments
  9. NURTEC ODT $179 8 payments
  10. Repatha $177 7 payments
  11. Other $4,018 172 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$197,986

Medicare's payments for the services billed

Medicare patients

409

Average age 82

Services billed

2,159

205 women, 204 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Ischemic heart disease 75%
Arthritis 75%
Heart failure 73%
Chronic kidney disease 61%
Atrial fibrillation 56%
Alzheimer's or dementia 52%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZENPEP
  • AIMMUNE THERAPEUTICS, INC. $146
$146 — —
Fetroja
  • Shionogi Inc $43
$43 — —
NURTEC ODT
  • PFIZER INC. $42
$42 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $21
$21 — —
NUZYRA
  • Paratek Pharmaceuticals, Inc. $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

254 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record